Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 145

Results For "NAL"

5545 News Found

HCAH Kolkata Center achieves NABH Certification
News | August 15, 2024

HCAH Kolkata Center achieves NABH Certification

Becomes the first rehab & recovery center in east India to earn NABH accreditation


Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr
News | August 15, 2024

Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr

India Business grew by 11.9% YoY to Rs. 1196.2 crore


ICMR and Panacea Biotec initiates Phase III clinical trial of DengiAll
Diagnostic Center | August 15, 2024

ICMR and Panacea Biotec initiates Phase III clinical trial of DengiAll

The clinical trial will be conducted at 19 sites with 10,335 participants across India


Generative AI is a top driver for cloud investments: Wipro FullStride Cloud Report
Digitisation | August 15, 2024

Generative AI is a top driver for cloud investments: Wipro FullStride Cloud Report

Majority of organizations are looking to increase investments in public and hybrid cloud


Evonik expands its formulation capabilities for lipid nanoparticles
News | August 15, 2024

Evonik expands its formulation capabilities for lipid nanoparticles

Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations


NHA and MUHS sign MoU to drive digital health education
News | August 14, 2024

NHA and MUHS sign MoU to drive digital health education

The partnership marks a significant milestone in integrating digital health education into medical curricula


Wanbury appoints Prakash Venkatraman as President of API Business
People | August 14, 2024

Wanbury appoints Prakash Venkatraman as President of API Business

He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years


Indian API companies to grow by 7-8% and operating profit margin to improve to 12-14% in FY2025: ICRA
Opinion | August 14, 2024

Indian API companies to grow by 7-8% and operating profit margin to improve to 12-14% in FY2025: ICRA

Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024


Pfizer announces results of ABRYSVO for RSV in immunocompromised adults
Diagnostic Center | August 13, 2024

Pfizer announces results of ABRYSVO for RSV in immunocompromised adults

These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV


Ashland completes second expansion of Viatel bioresorbable polymers manufacturing and R&D lab in Ireland
News | August 13, 2024

Ashland completes second expansion of Viatel bioresorbable polymers manufacturing and R&D lab in Ireland

This project is supported by the Irish Government through IDA Ireland